# US 2023/0134821 A1 · Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0134821 A1
- Document ID: US20230134821A1
- Status: Published application
- Kind: A1
- Application number: 17/966,227
- Filed: 2022-10-14
- Published: 2023-05-04
- Earliest claimed: 2018-09-05
- Assignees: The University of British Columbia
- Applicants: The University of British Columbia
- Inventors: ARTEM TCHERKASSOV; PAUL S. RENNIE; FUQIANG BAN; ERIC J.J. LEBLANC; LAVINIA A. CARABET; NADA LALLOUS; KRITI SINGH; HELENE MORIN; ANH-TIEN TON
- Web page: https://patentgrep.com/patent/US20230134821A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07C 237/22: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
- C07C 233/43: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
- C07C 233/56: having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
- C07C 235/20: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 237/12: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups (peptides C07K)
- C07C 237/42: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C07C 255/66: having cyano groups and nitrogen atoms being part of hydrazine or hydrazone groups bound to the same carbon skeleton
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 275/10: being further substituted by singly-bound oxygen atoms
- C07C 275/24: containing six-membered aromatic rings
- C07C 275/30: being further substituted by halogen atoms, or by nitro or nitroso groups
- C07C 311/18: to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C 311/19: to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 311/39: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C 323/60: with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- C07C 335/12: the carbon skeleton containing six-membered aromatic rings
- C07C 335/16: having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C 335/18: being further substituted by singly-bound oxygen atoms
- C07C 335/20: being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C 335/22: being further substituted by carboxyl groups
- C07C 381/00: Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07D 211/42: attached in position 3 or 5
- C07D 213/40: Acylated substituent nitrogen atom
- C07D 213/61: Halogen atoms or nitro radicals
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 265/30: not condensed with other rings
- C07D 265/36: condensed with one six-membered ring
- C07D 277/36: Sulfur atoms
- C07D 307/14: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 311/16: substituted in position 7
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 7/06: having 5 to 11 amino acids
- C07C 2601/08: the ring being saturated
- C07C 2601/16: the ring being unsaturated
- C07C 2603/74: Adamantanes
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 235/02: condensed with carbocyclic rings or ring systems
- C07D 271/12: condensed with carbocyclic rings or ring systems
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

## Claims

### Claim 1

A method of cancer treatment, the method comprising administering one or more compounds to a patient in need thereof, wherein the compounds have the structure of Formula III:
wherein,
A1 is absent;
A2 is absent;
T1 is H or CH3;
T2 is H or CH3;
D1 is O or S;
n1 is 0;
n2 is 0;
n3 is 1 or 2, wherein if n3 is 2, each D1 may be independently selected from O or S;
n4 is 0-3;
n5 is 0;
E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
and
wherein the cancer is selected from one or more of the following: prostate cancer; breast cancer; colon cancer; cervical cancer; small-cell lung carcinoma; neuroblastomas; osteosarcoma; glioblastoma; melanoma; and myeloid leukaemia.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is VPC-70551.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is selected from prostate cancer, breast cancer, colon cancer cervical cancer and small-cell lung carcinoma.

### Claim 4

A pharmaceutical composition for treating cancer, comprising a compound having the structure of Formula III:
wherein,
A1 is absent;
A2 is absent;
T1 is H or CH3;
T2 is H or CH3;
D1 is O or S;
n1 is 0;
n2 is 0;
n3 is 1 or 2, wherein if n3 is 2, each D1 may be independently selected from O or S;
n4 is 0-3;
n5 is 0;
E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the cancer is selected from one or more of the following: prostate cancer; breast cancer; colon cancer; cervical cancer; small-cell lung carcinoma; neuroblastomas; osteosarcoma; glioblastoma; melanoma; and myeloid leukaemia.

### Claim 6 (depends on 4)

The pharmaceutical composition of claim 4, wherein the compound having the structure

### Claim 7 (depends on 1)

The method of claim 1, wherein E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
and
L5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),

### Claim 8 (depends on 1)

The method of claim 1, wherein n1 is 0; n2 is 0; n3 is 1; and n5 is 0.

### Claim 9 (depends on 1)

The method of claim 1, wherein
E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,
E4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,
E5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,
L4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,
and
L5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2,

### Claim 10 (depends on 1)

The method of claim 1, wherein
E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
E4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
E5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
L4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or
and
L5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2), or

### Claim 11 (depends on 1)

The method of claim 1, wherein
E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
E4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
E5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
L4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
and
L5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or

### Claim 12 (depends on 1)

The method of claim 1, wherein
E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
E4 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
E5 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
L4 is H, CH3, CH2CH3, F, Cl, Br, CF3, or
and
L5 is H, CH3, CH2CH3, F, Cl, Br, CF3, or

### Claim 13 (depends on 1)

The method of claim 1, wherein
E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
E4 is H;
E5 is H;
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, or
L4 is H; and
L5 is H.

### Claim 14

A compound, the compound having the structure of Formula III:
wherein,
A1 is absent;
A2 is absent;
T1 is H or CH3;
T2 is H or CH3;
D1 is O or S;
n1 is 0;
n2 is 0;
n3 is 1 or 2, wherein if n3 is 2, each D1 may be independently selected from O or S;
n4 is 0-3;
n5 is 0;
E1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
E5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L1 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L2 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L3 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L4 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
L5 is H, CH3, CH2CH3, F, Cl, Br, CF3, OCF3, OCF2, S(═O)2(NH2), OCH2C(CH3)(CH2),
and
provided that the compound is not
